Videos

Shishir Khetan, MD, is a Principal Investigator and Senior Medical Director at Velocity. He’s also a leading expert for the Vaccine CARE Council. But as he explains in this video, he’s excited about the opportunities the CARE Council model is creating for investigators, even beyond vaccines. Through expert knowledge exchange — including mentoring and training … Read more

Heart disease remains the leading cause of death worldwide. The proliferation of heart issues — paired with lifestyle factors that complicate patient recruitment and study design — reflect an urgent need for expert-led clinical trials. Moreover, intersections among heart health and metabolic research offer promising opportunities to confront diseases affecting a growing, aging population, and … Read more

The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising. In light of the stark unmet needs in liver disease treatment — particularly for metabolic dysfunction-associated steatohepatitis (MASH) — there’s a pressing need for more sites equipped to effectively support advanced liver disease research. As Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, mentions … Read more

Évelyne Newton and Sylwia Kołodziej recently made the journey overseas to join our CARE Council summit in Durham, NC. Along with dozens of our physicians and operational, commercial, and recruitment leaders, they helped define a strategy to extend the reach of new and existing CARE Councils. As they mention in this video, by enhancing the … Read more

Despite a boom in tech funding and monumental advancements in AI/ML and in silico models, tech advancements have not yet translated into marked efficiency improvements at clinical research sites. Most clinical trials still fail to meet enrollment timelines, with most delays occurring at the site level. To gain efficiency, technology must enhance clinical trials at … Read more

As part of our integrated site infrastructure, Velocity has established specialized laboratory and diagnostic capabilities. This includes purpose-built, CLIA-certified lab facilities at all dedicated sites, as well as in-network PBMC processing at 30+ Velocity locations across the U.S. and Europe. As Nick Spittal, Chief Operations Officer, explains in this video, Velocity is also using these … Read more

To bring equitable products to market, clinical trials need proportionate representation. Reaching the right patients must be prioritized at the site level, where clinical research is most visible in communities. Therefore, Velocity is heavily invested in leveraging the power of local influence to drive change. Our focus is on managing what we can effectively control … Read more

As Nicholas Campbell explains, good business can also be good for the environment. As Velocity improves lives by accelerating the development of new therapies, we can also build a healthier tomorrow by conducting trials in a sustainable way. How can Velocity deliver more efficient trials? Enhanced site enrollment forecasting to minimize overages, alongside reduced investigational product distribution … Read more